Fig. 2. Interplay of rosiglitazone and MED1 binding to PPARγ–LBD measured by 2D fluorescence anisotropy. (A) 2D-FA protein-titration of PPARγ to 10 nM labeled MED1 at various rosiglitazone concentrations (0–200 μM). (B) 2D-FA compound titration of rosiglitazone to 10 nM labeled MED1 with various concentrations of PPARγ (0–20 μM; blue to black).
